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a b s t r a c t
We developed adenovirus serotype 5 (Ad5) vectors displaying the sigma 1 protein from reovirus as
mucosal vaccines. Ad5-sigma retargets to JAM-1 and sialic acid, but has 40-fold reduced gene delivery
when compared to Ad5. While weaker at transduction, Ad5-sigma generates stronger T cell responses
than Ad5 when used for mucosal immunization. In this work, new Ad5-ﬁber-sigma vectors were
generated by varying the number of ﬁber β-spiral shaft repeats (R) between the ﬁber tail and sigma.
Increasing chimera length led to decreasing insertion of these proteinsAd5 virions. Ad-R3 and R14
vectors effectively targeted JAM-1 in vitro while R20 did not. When wereused to immunize mice by the
intranasal route, Ad5-R3-sigma produced higher serum and vaginal antibody responses than Ad5. These
data suggest optimized Ad-sigma vectors may be useful vectors for mucosal vaccination.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Most pathogens enter the body at mucosal surfaces. Generating
robust “barrier protection” at mucosal surfaces may therefore be
an ideal strategy to block infections before they become systemic
(reviewed in Lycke, 2012).
Adenoviruses (Ads) are non-enveloped DNA viruses (reviewed in
Campos and Barry, 2007). Ads are potent vectors for gene-based
vaccination (Lasaro and Ertl, 2009). Adenovirus serotype 5 (Ad5)
binds to the coxsackie and adenovirus receptor (CAR) using its
trimeric ﬁber protein (Fig. 1 and reviewed in Khare et al., 2011).
Theﬁber protein consists of a 44 amino acid “tail” domain on its
n-terminus that docks into the penton base of the viral icosahedron,
a 21 β-spiral repeats in its shaft domain, and a c-terminal
CAR-binding “knob” domain (Fig. 1).
Reoviruses are non-enveloped RNA viruses that infect gut
mucosa by binding junctional adhesion molecule 1 (JAM-1) and
sialic acid (Kirchner et al., 2008). Reoviruses display a trimeric
protein for receptor binding that is called sigma 1. Despite having
evolved separately and binding different receptors, sigma 1 has a
shaft domain bearing β-spiral repeats that are remarkably similar
to those in adenovirus ﬁbers (Forrest et al. (2003) and Fig. 1).
Because Ads naturally cause a number of ocular, respiratory,
and digestive infections, they can be one of the most robust
vectors for vaccination at mucosal surfaces. While this is true,
CAR-utilizing adenoviruses may not be optimal for mucosal
vaccination because mucosal epithelial cells do not actually dis-
play CAR on their luminal surfaces (Grubb et al., 1994; Zabner
et al., 1997). Instead, CAR is sequestered on the basolateral surface
of mucosal cells making infection there less efﬁcient. In contrast,
the T3D reovirus sigma 1 protein binds to sialic acid that is
expressed on nearly all mucosal epithelial cells. Sigma 1 also binds
JAM-1, which is expressed on microfold cells (M cells) of Peyer's
patches in the lumen of the gut. JAM-1 is also expressed on den-
dritic cells (Mercier et al., 2004). In contrast, CAR is not expressed
on these professional antigen-presenting cells.
Given the desire to improve mucosal vaccination, we pre-
viously generated a chimeric adenovirus that displays the sigma
1 protein (Mercier et al. (2004) and Fig. 1). This was accomplished
by replacing the virion docking motif of the sigma 1 protein
from reovirus T3D with the 44 amino acid Ad5 ﬁber tail. When the
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tail-sigma 1 protein was engineered into Ad5 vectors in place of
the ﬁber, sigma 1 was successfully displayed on Ad5 virions. When
tested in vitro, Ad5-sigma 1 was shown to no longer bind CAR,
but instead bind to sialic acid and JAM-1 (Mercier et al., 2004).
When Ad5-sigma 1 was subsequently tested in vivo in mice, it was
40-fold less efﬁcient at transducing muscle or nasal mucosa than
Ad5 (Weaver et al., 2012). This weak transduction correlated to
weak antibody production against its transgene product. This
weak vector function could be due to defects in either end of the
chimeric protein. The tail-sigma fusion might be inefﬁcient at
docking into the Ad5 penton base on the viral icosahedron. Alte-
rnately, this one fusion protein might not display sigma 1 in a
fashion that allowed efﬁcient use of its cognate receptors. In this
work, we engineered a series of ﬁber-sigma fusion proteins and
displayed them on Ad5 to test for in vivo transduction and
antibody production.
Results
Construction of ﬁber-sigma chimeric proteins
To allow the reovirus sigma protein to dock into the Ad penton
base, sigma 1 was originally fused to just the minimal 44 amino
acid tail of the ﬁber tail (Fig. 1 and Mercier et al. (2004)). The Ad5
ﬁber has 21 β-turn repeats in its shaft that provides the bulk of the
trimer's length. The third β-turn, repeat 3 (R3), contains a four
amino acid insertion that provides ﬂexibility to the shaft of ﬁber
(Nicklin et al., 2005; Wu and Nemerow, 2004). We hypothesized
that including tail-R1–R2–R3 with this ﬂexibility motif might
enhance Ad-sigma functionality. It was also possible that adding
more ﬁber repeats to the fusions might optimize the protein for
mucosal infection.
To test this, a series of ﬁber-sigma chimeras were generated
and these were cloned into expression plasmids (Fig. 1). Each of
the plasmids were transfected into 293 cells and cell lysates were
evaluated by western blot using an antibody against the ﬁber tail
(Fig. 2). Increasing the number of ﬁber shaft repeats from 3 (R3) to
20 (R20) led to the expression of increasing longer ﬁber-sigma
chimeric proteins. Notably, all of the chimeras trimerized, suggest-
ing that they had the potential to be incorporated into the penton
base of Ad5 virions (Parrott et al., 2003).
Sigma 1 virus generation
R3, R14, and R20 ﬁber-sigma chimeric proteins were selected
for further testing. Each was used to replace the ﬁber gene in
replication-defective E1/E3 deleted Ad5 vectors expressing the
Aequorea victoria green ﬂuorescent protein fused to ﬁreﬂy lucifer-
ase (GFPLuc) by homologous recombination in bacteria as in
(Mercier et al., 2004). The recombinants were veriﬁed by sequen-
cing and then rescued in ﬁber-expressing 633 cells (Von Seggern
et al., 2000) as in Mercier et al., 2004. In their ﬁnal round of
ampliﬁcation, the viruses were produced in 293 cells for display
only the virally-encoded sigma chimera (Mercier et al., 2004).
Virus composition
Ad5, R3, R14, and R20 ﬁber-sigma chimera viruses were
puriﬁed by CsCl banding. These puriﬁed virions were separated
by SDS-PAGE and stained with Sypro Rubytm to detect all virion
proteins (Fig. 3A). All viruses had normal virion capsomers
including hexon, penton, IIIa, V, VI, and VII. There are normally
36 copies of ﬁber per virion. Fiber and ﬁber-sigma chimeras are
difﬁcult to discern when staining for total protein, since the 60
copy IIIa protein overlaps these lower copy proteins. These were
detected by western blot with an antibody directed against the
ﬁber tail (Fig. 3B). Western blotting detected wild type ﬁber as
well as the larger sigma chimeras in all the viruses. As chimera size
increased, progressively less ﬁber-tail detected protein appeared
to be incorporated. R3-sigma intensity appeared to be similar to
that of the ﬁber, but there was markedly less R14 protein on the
puriﬁed virus and R20 was barely detectable. Adenoviruses lacking
ﬁber fail to mature and proteolytically cleave precursor proteins in
the virion including processing pVI and pVII to VI and VII (Legrand
et al., 1999). While Ad5, R3, and R14 virions appeared fully mature,
R20 virions had pVI and pVII bands indicated they were immature
in this slightly overloaded lane (Fig. 3A). This as well the observed
Fig. 1. Cartoon of ﬁber-sigma chimeric proteins.
Fig. 2. Western blot of ﬁber-sigma chimeras. The indicated ﬁber chimeras shown in
Fig. 1 were used to transfect cells and cell lysates were boiled in standard Laemli
loading buffer to observe ﬁber monomers. To observe trimers, samples were mixed
with loading buffer with reduced SDS and were not boiled prior to loading. After
SDS-PAGE and transfer to PVDF membranes, the ﬁber chimeras were detected by
western blot with an antibody against the Ad5 ﬁber tail.
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low R20 sigma encapsidation makes it likely that a high fraction of
Ad5–R20 virus are essentially “ﬁberless“ (Legrand et al., 1999).
Virus stability
Ad5, R3, R14, and R20 ﬁber-sigma chimera viruses were tested for
stability by exposing them to a series of freeze/thaw cycles and by
treatment at 47.5 1C. Following these treatments, the virions were
used to infect human lung A549 cells and functionality was measured
by luciferase assay (Fig. 3C and D). Since the viruses were stored at
-80 1C, thawing them for any use constitutes one freeze/thaw cycle.
Treatment of human lung A549 cells with freshly thawed viruses
produced highest transduction by unmodiﬁed Ad5 (Figs. 3C and 4). R3
and R14 mediated 80 to 100-fold lower transduction than Ad5 on
A549 cells. In contrast, R20 was 4-fold lower than R3 and R14 and
300-fold lower than Ad5 on these cells. Additional freeze/thaw cycles
had little effect on virion transduction (Fig. 3C). Surprisingly, additional
cycles appeared to slightly increase R3 activity.
Incubation of the viruses at 47.5 1C for 10 or more minutes
reduced transduction for all of the viruses relative to untreated
viruses (Fig. 3D). 30 min treatment of Ad5 reduced its activity
1000-fold. The same treatment reduced R3 activity 10-fold. While
their fold effects were quite different, 30 min treatment essentially
equalized the activity to all of the viruses. These data suggested
that the sigma viruses were not particularly unstable relative to
Ad5 at least by these interventions.
Virus activity in vitro
Previous work showed that the original ﬁber-tail-sigma virus
infected via interactions with JAM1 (Mercier et al., 2004). However,
subsequent comparisons of Ad5 with tail-sigma virus showed that
this virus mediated markedly weaker in vitro and in vivo transduc-
tion, but better T cell responses in vivo (Weaver et al., 2012). To test
this for the new viruses, Ad5, R3, R14, and R20 ﬁber-sigma chimera
viruses were used to infect several cell lines with varied JAM1
expression and virus functionality was assessed by luciferase assay
(Fig. 4). Chinese hamster ovary (CHO) cells lack both CAR and JAM1,
but express αv integrins. On these cells, transduction was equal
between Ad5, R3, and R14. R20 activity was 20-fold lower than the
other viruses. On CHO-JAM1 cells that were modiﬁed to express the
human protein, R3 and R14 activity was signiﬁcantly higher than
Ad5 demonstrating that the viruses use the sigma 1 cognate
receptor. In contrast R20 was no better than Ad5. Syrian hamsters
Fig. 3. Viral composition and stability. (A) Total protein composition of CsCl-puriﬁed viruses. 1010 vp of the indicated virus was separated on SDS-PAGE gels and stained with
Sypro Ruby to detect proteins. (B) Western blot with anti-Ad5 tail antibody on the same CsCl-puriﬁed virions from panel A. (C) Effects of serial freeze/thaw on viral function.
The indicated viruses were thawed from 80 1C storage. This constituted freeze/thaw 1. The virions were diluted in media and freeze/thawed additional times and these
solutions were used to infect A549 cells at a multiplicity of infection (MOI) of 10,000 vp/cell. Transduction was measured by luciferase assay. (D) Effects of heat treatment on
viral function. The indicated viruses were thawed from 80 1C storage and were diluted in media. Each virus was treated for the indicated times at 47.5 1C and immediately
chilled on ice prior to infection of A549 cells and luciferase assay (n¼2).
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and their HAK kidney cancer cells are permissive for Ad5 infection
presumably due to expression of the hamster CAR protein (Thomas
et al., 2007). HAK cells were transfected with human JAM1 and
tested with the viruses (Fig. 4). On these cells, Ad5 still mediated
superior transduction when compared to the sigma viruses, but this
was only 3 to 4-fold better than the R3 and R14. R20 transduction
was again lower than the other three viruses.
Mucosal transduction by Ad-sigma variants
Groups of 10 female BALB/c mice were inoculated with 1010
virus particles (vp) of Ad5, Ad5-R3-sigma, or Ad5-R14-sigma by
the intranasal route and luciferase expression was monitored
(Fig. 5). Under these conditions, Ad5 and Ad-R3 mediated similar
luciferase activity (not statistically different (ns) by one way
ANOVA). In contrast, Ad-R14 generated luciferase levels that were
similar to the background in the control animals.
Antibody responses generated by ad-sigma variants
At the six week time point, anti-GFP antibody levels were also
measured from the serum and from vaginal washes of the animals
(Fig. 6A and B). R14 generated responses that were no better than
controls. Ad5 produced detectable serum antibodies against GFP
with this one immunization. In contrast, R3 generated stronger
serum and vaginal wash antibodies than any of the other vectors
(po0.05). Notably, Ad5-R3-sigma generated these more robust
mucosal immune after single intranasal immunization at a site
quite distant from the site of vaccination.
Discussion
We previously replaced the Ad5 ﬁber with the sialic acid and
JAM-1-binding reovirus T3D sigma 1 protein in an attempt to
improve adenovirus vaccines for mucosal immunization. While
this original Ad-tail-sigma vector was indeed retargeted to these
new receptors, its overall in vivo transduction activity was mark-
edly weaker than the original Ad5 vector. This weak raw transduc-
tion translated to a weak ability to generate antibodies against
HIV-1 gag when compared to the benchmark Ad5 vector (Weaver
et al., 2012). While Ad-tail-sigma had overall weak transduction
potency, it surprisingly generated markedly better T cell responses
than Ad5 in vivo (Weaver et al., 2012). When Ad-tail-sigma was
combined with Ad5 as a vaccine, the two synergized to generate
higher antibody responses than either alone (Weaver et al., 2012).
This suggested that sigma 1 may indeed have beneﬁts for mucosal
vaccination, if the vectors ability to deliver genes could be
improved.
In this work, we aimed to improve the functionality of Ad-
sigma by modifying the fusion between the Ad5 ﬁber tail and the
reovirus sigma 1 protein. Any sigma chimera must have the ﬁber
tail to dock into the penton base of the Ad5 icosahedron. The
original ﬁber tail-sigma chimera had only this tail domain. We
therefore speculated that adding repeats from the Ad5 ﬁber might
either improve penton base docking of the chimera or improve
sigma's ability to bind its receptors.
We show that including the ﬁrst three β-turn repeats of the
Ad5 ﬁber markedly improved vector function in vivo. We speculate
that this improvement may be primarily due to the inclusion of
the third repeat (R3) from the Ad5 ﬁber. This β spiral repeat is
Fig. 4. In vitro transduction on different cells. The indicated cells were plated in 96
well plates and treated with the indicated viruses at an MOI of 10,000 vp/cell in
replicates of 8 or 12. Transduction was assessed by luciferase assay. A549 cells are
human lung cells. HAK-CD46 cells are hamsters cells that are permissive to species
C Ad infection that are stably transfected with human CD46. CHO cells are Chinese
hamster ovary cells that lack both CAR and JAM1, but that express αv integrins.
CHO-CD46 cells are CHO cells that are stably transfected with human CD46. Error
bars indicate standard error. nn indicates po0.01 and nnnn indicates po0.0001 by
one way ANOVA.
Fig. 5. In vivo transduction by Ad5 and Ad5 displaying sigma chimeras. Mice were
immunized intranasally with the indicated vectors and were imaged 4 days later.
Error bars indicate standard error. nn indicates po0.01 by one way ANOVA.
Fig. 6. Systemic and mucosal antibody responses generated by sigma chimeras.
Mice were immunized intranasally as in Fig. 5 and serum or vaginal washes were
collected 6 weeks after single immunization. Antibodies against GFP were mea-
sured by serial dilution in ELISA. Error bars indicate standard error. * designates
po0.05 by ANOVA.
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interrupted by a four amino acid insertion that is thought to
provide ﬂexibility to the shaft of ﬁber (Nicklin et al., 2005; Wu and
Nemerow, 2004). For Ad5, this ﬂexibility allows the ﬁber to bend
nearly 901 allowing the CAR binding motifs on the sides of the
knob domain to engage their receptor. This ability to bend may
also move the large 35 nm ﬁber out of proximity with the penton
base allowing its RGD motif to engage αV integrins (Nicklin et al.,
2005; Wu and Nemerow, 2004). For Ad-sigma, we hypothesize
that including repeat 3 may improve interactions with sigma
receptors. Alternately, addition of this ﬂexibility motif may allow
the chimera to dock more efﬁciently into the penton base during
encapsidation.
The R3, R14, and R20 chimeras all contain the R3 ﬂexibility
domain. In vitro comparisons between the viruses demonstrated
that R3 and R14 mediated similar transduction on several cell
types whereas R20 was markedly weaker. Notably, both R3 and
R14 were able to utilize JAM1 on target cells and that only these
viruses utilized JAM-1 as a receptor. The R20 virus was largely
ineffective on all cells. This difference in functionality may be due
to the overall size of the chimeric proteins. Ad5 ﬁber is approxi-
mately 35 nm long (Fig. 1). In contrast, native sigma 1 on reovirus
is nearly 48 nm in length, so it is already larger than the ﬁber.
Adding ﬁber tail and the ﬁrst three repeats to sigma should make
this chimera slightly longer than native sigma 1. In contrast, R14
and R20 have 14 and 20 β spiral repeats from ﬁber which likely
adds more than 20 to 30 nm of length to these chimeras. This
would make these proteins nearly 68 to 78 nm in length or nearly
twice as long as Ad5 ﬁber itself.
Analysis of the protein content of puriﬁed virions revealed
that Ad5-R3 and R14 had essentially normal viral protein com-
position (with the exception of ﬁber). In contrast, R20 virions
appeared immature as indicated by the presence of unprocessed
pVI and pVII in the virions. This observation was concordant with
the observation that very little R20 chimeric protein was present
on CsCl-banded virions. This suggests that the very long R20
chimera was poorly packaged in virions during assembly. If R20
was packaged and subsequently lost from virions during CsCl
banding, the virus should not have uncleaved pVI and pVII
proteins.
With increasing chimera size, less of the fusion proteins were
incorporated. R3 appeared to be incorporated to similar levels as
the ﬁber, although this was not entirely clear as the ﬁber bands on
western blot were sharp and the R3 band was broader. R14
encapsidation was lower than R3, but better than R20. This lower
encapsidation did not seem to interfere overtly with virion
maturation or in vitro transduction on cell lines. In contrast, R14
was ineffective in vivo for gene delivery or vaccination than Ad5 or
R3. This suggests that R14 may be less stable in vivo, perhaps due
to proteolysis or other effects. Stability testing by freeze thaw and
heating did not reveal any fundamental instability associated with
R3, R14, or R20 relative to Ad5 suggesting that R14 may not suffer
simple stability problem in vivo. However, failure to fully occupy
all penton base sites on the Ad5 virion may well make these
viruses susceptible to proteolysis or nuclease attack in vivo. Finally,
the exceptional length of R14 protein may reduce its interactions
with JAM1 that is sequestered in junctional adhesions in mucosa
in vivo.
The new R3-sigma vector mediated similar transduction to Ad5
after intranasal immunization of mice. In contrast, R3 generated
markedly more robust systemic and mucosal antibody responses
than the benchmark Ad5 vector. This effect was similar to the
observation that mixing the original Ad5-tail-sigma virus with Ad5
generates stronger antibodies than Ad5 alone or tail-sigma alone.
This suggests that the improved R3-sigma may now harness some
of the unique functionality of this new receptor targeting protein
for mucosal vaccination.
These studies were performed in the context of human Ad5
vectors using sigma 1 protein from T3D reovirus. Ad5 is arguably
the worst serotype for use in humans due to pre-existing immu-
nity in 27 to 100% of humans (Abbink et al., 2007). The choice of
Ad5 as a platform is historical as this was the original vector that
was modiﬁed with sigma 1 (Mercier et al., 2004). The improved
functionality of R3 now justiﬁes its use in lower seroprevalence Ad
vectors. Reovirus is also a human pathogen that can have high
seroprevalence (Tai et al., 2005). Children become increasingly
seropositive to reovirus T3D over the ﬁrst 5 years of life with
approximately 50% having binding antibodies in their sera to the
virus (Tai et al., 2005). Adults would seem to have similar or higher
seroprevalence as indicated by the presence of maternally trans-
mitted anti-T3D antibodies in 75% of the sera of tested infants (Tai
et al., 2005). While these data suggest that anti-sigma antibodies
may challenge an Ad-sigma vaccine in humans, these titers are
based on reovirus binding antibodies rather than neutralizing
antibodies, so it is unclear how well they would repel an Ad-
sigma vaccine. Pilot studies showed that priming with the original
Ad5-tail-sigma did not prevent the ability of Ad5-tail-sigma to
mediate an effective boost in anti-HIV gag antibodies (data not
shown). This suggests that anti-sigma antibodies may not disable
the use of this retargeting platform as a vaccine. However, work is
underway to identify sigma analogs that may evade theoretical
neutralization in humans.
This work was initiated to improve mucosal vaccination with
adenovirus gene-based vaccines. These results are notable, since
mice were vaccinated only a single time with Ad-R3-sigma, yet
provoked robust immune responses without any boosting. Ad-R3-
sigma not only generated antibody responses in the serum, but
also importantly generated antibodies in vaginal washes. This
suggests that Ad-R3-sigma may be able to establish a barrier to
infection at mucosal surfaces where most pathogens enter the
body. This single vaccination with R3 also generated systemic
antibodies in the blood. This suggests that R3 can establish
systemic immunity to serve as an immunological back up should
vaccine protection at the mucosal barrier protection fail and
infections spread beyond the site of entry. Considering the
burgeoning interest in mucosal vaccines, optimized Ad-sigma
vectors may have utility against a number of mucosal pathogens
including HIV-1, inﬂuenza, and emerging pathogens like Ebola
virus and MERS.
Materials and methods
Generation of chimeric ﬁber-sigma T3D proteins
Fiber-sigma 1 fusion genes were generated by overlap PCR and
standard cloning procedures in a manner similar to that used to
produce the original fusion protein (Mercier et al., 2004). These
were cloned in place of the Ad5 ﬁber protein in a CMV expression
plasmid with the adenovirus tripartite leader to enhance expres-
sion and with a zeocin resistance gene between the chimera and
the Ad E4 domain for recombination in bacteria (Campos and
Barry, 2004). For expression testing, the plasmids were transfected
into 293 cells with Polyfect (Qiagen, Hilden, Germany).
Western blot analysis for ﬁber and sigma chimera expression
Transfected cells were lysed in standard Laemli SDS-PAGE
loading buffer or with trimerization loading buffer with reduced
SDS that preserves ﬁber trimerization in SDS-PAGE (Parrott et al.,
2003). Standard Laemli sample were heated for 5 min at 95 1C
prior to loading. Trimerization samples were not heated prior to
loading. The samples were separated on SDS-PAGE gels, transfered
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to PVDF membranes, and chimeras were detected with mouse 4D2
antibody against the ﬁber tail (Abcam).
Generation of sigma-modiﬁed Ad5
To generate sigma-modiﬁed Ad5 vectors, ﬁber-sigma-E4 cas-
settes were recombined into E1/E3-deleted Ad5 plasmids by co-
transformation in recombinogenic bacteria as in Campos and
Barry, 2004. Fiber-sigma cassettes were recombined into pAd-
GFPLuc expressing the Aequorea victoria jellyﬁsh GFP fused in
place of the start methionine of ﬁreﬂy luciferase. Once generated
and conﬁrmed by sequencing, these adenovirus genomes were
linearized with Pac I and transfected into ﬁber expressing 633 cells
(Von Seggern et al., 2000) in the presence of 0.3 μM dexametha-
sone as in (Mercier et al., 2004). The viruses were ampliﬁed by
serial passage in 633 cells until the ﬁnal round of ampliﬁcation in
293 cells to generate viruses that display only the virally-encoded
sigma 1 chimera. For their ﬁnal round of ampliﬁcation, viruses
were puriﬁed from 633 cells by CsCl banding to avoid transfer of
excess Ad5 ﬁber protein produced from these helper cells as these
can contaminate subsequent virions. These CsCl-banded viruses
from 633 cells were then used infect 10 plate CellStacks of 293
cells to produce virions displaying only the virally-encoded sigma
chimera (Mercier et al., 2004). Viruses were puriﬁed twice by CsCl
gradient centrifugation, desalted, quantitated by OD260, and
frozen at 80 1C in 50 mM Tris, 0.5 M sucrose pH 8.
Virion protein analysis
CsCl-puriﬁed viruses were separated on 7–15% Tris-glycine
SDS-PAGE gels (Biorad). To detect total viral protein, the gels were
stained with Sypro Rubytm (Life Technologies). Fiber and ﬁber tail-
sigma chimeras were detected by western blot with custom rabbit
antibody 1561 raised ﬁber tail peptide ARPSEDTFNPVY (Mercier et
al., 2004).
Cell culture
293, A549, CHO, and HAK cells were purchased from ATCC and
were maintained in Dulbecco's Modiﬁed Eagle Medium supple-
mented with 10% fetal bovine serum (FBS; HyClone, Rockford, IL)
and penicillin/streptomycin at 100 U/mL (invitrogen). Chinese
hamster ovary (CHO) and Syrian hamster kidney (HAK) cells were
modiﬁed to express the Junctional Adhesion Molecule 1 (JAM-1)
receptor for T3D reovirus by stable transfection with pCDNA-JAM1
as in Ref. Mercier et al., 2004.
In vitro virus transduction
Viruses were thawed and diluted to 2109 virus particles (vp)
per ml of DMEM tissue culture media (Life Technologies). Viruses
were either untreated, were freeze-thawed a series of times, or
were treated for varied times at 47.5 1C. As the viruses were
originally frozen at 80 1C, all were by deﬁnition freeze/thawed
a single time. Freeze/thaw 1 represents viruses that were only
thawed this ﬁrst time. 100 ml of untreated or treated virions were
added to the indicated cells in 96 well dishes in 100 ml of DMEM
supplemented with 10% fetal bovine serum and penicillin/strepto-
mycin (Life Technologies). Cells were incubated for 48 to 72 h and
virus transduction was measured by luciferase expression using
Bright Glow reagent (Promega) on a Beckman Coulter DTX 880
Multimode Detector.
Animals
Six weeks old female BALB/c mice were maintained under
Association for Assessment and Accreditation of Laboratory Ani-
mal Care (AALAC) guidelines in the Mayo Clinic Animal Facility
after approval by the Mayo Clinic Institutional Animal Care and
Use Committee. All animal experiments were performed in accor-
dance with the provisions of the Animal Welfare Act, the PHS
Animal Welfare Policy, and the principles of the NIH Guide for the
Care and Use of Laboratory Animals. Mice were immunized
intranasally (i.n.) with 11010 virus particles (vp)/mouse in a
20 ml total volume (10 ml per nare) and were imaged and samples
taken for immune assays in the timelines described below.
In vivo luciferase imaging
Mice were imaged at varied times on an in vivo F Imaging
System (Kodak) or a Lumazone Imaging System (Roper) as in Ref.
Weaver et al., 2012. Mice were anesthetized with ketamine/
xylazine, injected intraperitonealy (i.p.) with 150 ml of 20 mg/ml
d-luciferin, and were placed in the imager after 5 min to allow
distribution of the substrate. Images were taken by a 10-min
exposure with 22 binning using no ﬁlters and no photo-
multiplication. Each image was background subtracted and
photons were quantitated with the Lumazone Imaging Software.
Enzyme linked immunosorbent assay (ELISA)
ELISAs were performed as described in Ref. Weaver et al., 2012.
Brieﬂy, Immulon 4 HBX plates were coated with 100 ml of
recombinant luciferase or GFP protein at 1 mg/ml in PBS overnight
at 4 1C. The plates were blocked 2 mg/ml BSA and serial dilutions
of serum or vaginal washes were added to the plate for 1 h at room
temperature. The plates were washed 5 times with PBS and 100 ml
of Goat anti-mouse HRP conjugated antibody diluted 1:2000 in
PBS with BSA (1 mg/ml) was added for 1 h at room temperature.
The plates were washed 5 times with PBS and 100 ml Ultra TMB-
ELISA substrate was added for 1 h. Reactions were stopped with
50 ml of 2 M sulfuric acid and analyzed at 450 nm using a Beckman
Coulter DTX 880 Multimode Detector.
Statistical analyses
Data was graphed and analyzed with GraphPad Prism
6 software.
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